sglt2 inhibitor glp 1 agonist combination GLP-1 Receptor Therapy With and Without Inhibitors in Patients With Type 2 Diabetes Frontiers | Effects of SGLT2

Description

10.1097/JCP.0000000000000596 311

Beyond design, the most player-friendly environments prioritize fair bonus structures with realistic time windows, letting newcomers learn mechanics without feeling rushed

Eur Heart J Cardiovasc Pharmacother 10(1):79

Abbreviations ADA: American Diabetes Association AE: Adverse event ASCVD: Atherosclerotic cardiovascular disease CI: Confidence interval CKD: Chronic kidney disease CVOT: Cardiovascular outcomes trial EASD: European Association for the Study of Diabetes eGFR: Estimated glomerular filtration rate GLP-1RA: Glucagon-like peptide-1 receptor agonist HbA1c: Hemoglobin A1c HF: Heart failure HHF: Hospitalization for heart failure HR: Hazard ratio MACE: Major adverse cardiovascular events OR: Odds ratio RCT: Randomized controlled trial RR: Relative risk SBP: Systolic blood pressure SGLT2i: Sodium-glucose cotransporter-2 inhibitor T2DM: Type 2 diabetes mellitus References Daz-Trastoy O, Villar-Taibo R, Sifontes-Dubn M, Mozo-Pealver H, Bernabeu-Morn I, Cabezas-Agrcola JM, et al